Search for: "Mylan Pharmaceuticals v. FDA"
Results 61 - 80
of 233
Sorted by Relevance
|
Sort by Date
2 Feb 2011, 3:52 am
KG (EPLAW) US: Another weeks, another missive on BPCIA exclusivity (FDA Law Blog) US: The Preserve Access to Affordable Generics Act resurfaces early in the 112th Congress (FDA Law Blog) US: Data or market exclusivity? [read post]
8 May 2019, 7:14 am
” It’s not enough to put an unapproved drug on the market with a FDA-ish package insert, according to Mylan Labs., Inc. v. [read post]
18 Jul 2011, 8:21 am
Mylan, Takeda v. [read post]
3 Jul 2007, 10:47 am
Mylan Labs., 417 F. [read post]
4 Aug 2010, 12:21 am
Mylan Pharmaceuticals Inc. [read post]
3 Feb 2010, 2:00 am
Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O) EU: ‘Victory’ against biopiracy - EPO revokes Schwabe Pharmaceuticals' pelargonium extract patent (Spicy IP) (IP Watch) General Another case for indigenous knowledge protection, but how? [read post]
21 Feb 2014, 8:53 am
Mylan, Inc., 911 F. [read post]
24 Nov 2010, 12:37 am
General Global pharmaceutical linkage regulations: A consortium framework (IP Osgoode) Pfizer rolling out generics to grab off-patent market (GenericsWeb) Australia: Too little too late: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) and the judicial discretion to amend a patent (IP Whiteboard) Brazil: You lost your chance! [read post]
9 Sep 2008, 1:28 am
In re Omeprazole Patent Litigation (Astrazeneca v. [read post]
11 Jan 2022, 6:04 am
Mylan Pharmaceuticals Inc. [read post]
29 Mar 2011, 9:19 pm
General Pharmaceutical, biotechnology and chemical inventions – world protection and exploitation (FDA Law Blog) Gene patents on the high seas: who owns the ocean’s IP? [read post]
2 Sep 2009, 11:22 pm
Mylan Laboratories, Inc., 2008 WL 4813311, at *6-7 (D. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
12 Apr 2017, 8:44 am
Torrent Pharma, Apotex, and Mylan (Fed. [read post]
5 May 2010, 4:46 am
Mylan Pharmaceuticals Inc. et al. [read post]
17 Apr 2009, 12:00 am
Ltd. sues 11 generics companies over Levaquin patents (Law 360) Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat) Lexapro (Escitalopram) - Baldwin’s rules explained (The SPC Blog) Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360) Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition against Wockhardt… [read post]
5 Dec 2008, 1:00 pm
FDA issues draft guidance on submission of patent information for certain old antibiotics (FDA Law Blog) US: FDA publishes new guidance on contents of a complete submission for the evaluation of proprietary names (FDA Law Blog) USPTO appeals Wyeth v Dudas decision on patent term adjustment calculation; more patentees (including Molecular Insight and Biogen) follow Wyeth’s lead in seeking additional patent term adjustment (IP Updates) (Patent… [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to… [read post]
